Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Development and Validation of a Computational Model Ensemble for the Early Detection of BCRP/ABCG2 Substrates during the Drug Design Stage.

Gantner ME, Peroni RN, Morales JF, Villalba ML, Ruiz ME, Talevi A.

J Chem Inf Model. 2017 Aug 28;57(8):1868-1880. doi: 10.1021/acs.jcim.7b00016. Epub 2017 Aug 8.

PMID:
28708399
2.

Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.

Morales JF, Montoto SS, Fagiolino P, Ruiz ME.

Mini Rev Med Chem. 2017;17(3):247-257. Review.

PMID:
27739359
3.

Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.

Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C.

Clin Cancer Res. 2017 Jan 15;23(2):478-488. doi: 10.1158/1078-0432.CCR-16-1203. Epub 2016 Aug 17.

PMID:
27535982
4.

Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.

Morales JF, Yu B, Perez G, Mesa KA, Alexander DL, Berman PW.

Mol Immunol. 2016 Sep;77:14-25. doi: 10.1016/j.molimm.2016.07.003. Epub 2016 Jul 21.

PMID:
27449907
5.

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW.

N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18.

6.

Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.

Doran RC, Morales JF, To B, Morin TJ, Theolis R Jr, O'Rourke SM, Yu B, Mesa KA, Berman PW.

Mol Immunol. 2014 Nov;62(1):219-226. doi: 10.1016/j.molimm.2014.06.025. Epub 2014 Jul 11.

7.

The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis.

Kozak I, Vaidya V, Van Natta ML, Pak JW, May KP, Thorne JE; Studies of the Ocular Complications of AIDS Research Group.

Invest Ophthalmol Vis Sci. 2014 Jun 12;55(7):4304-12. doi: 10.1167/iovs.14-14479.

8.

Risk factors for reduced glomerular filtration rate in a Nicaraguan community affected by Mesoamerican nephropathy.

Raines N, González M, Wyatt C, Kurzrok M, Pool C, Lemma T, Weiss I, Marín C, Prado V, Marcas E, Mayorga K, Morales JF, Aragón A, Sheffield P.

MEDICC Rev. 2014 Apr;16(2):16-22.

9.

HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.

Morales JF, Morin TJ, Yu B, Tatsuno GP, O'Rourke SM, Theolis R Jr, Mesa KA, Berman PW.

J Biol Chem. 2014 Jul 25;289(30):20526-42.

10.

Higher moral obligations of tolerance toward other minorities: an extra burden on stigmatized groups.

Fernández S, Branscombe NR, Saguy T, Gómez A, Morales JF.

Pers Soc Psychol Bull. 2014 Mar;40(3):363-76. doi: 10.1177/0146167213512208. Epub 2013 Nov 19.

PMID:
24253193
11.

Organizational injustice: third parties' reactions to mistreatment of employee.

Topa G, Moriano JA, Morales JF.

Psicothema. 2013;25(2):214-21. doi: 10.7334/psicothema2012.237.

PMID:
23628536
12.

Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy.

Jabs DA, Ahuja A, Van Natta M, Dunn JP, Yeh S; Studies of the Ocular Complications of AIDS Research Group.

Ophthalmology. 2013 Jun;120(6):1262-70. doi: 10.1016/j.ophtha.2012.11.023. Epub 2013 Feb 16.

13.

Non-cytomegalovirus ocular opportunistic infections in patients with acquired immunodeficiency syndrome.

Gangaputra S, Drye L, Vaidya V, Thorne JE, Jabs DA, Lyon AT; Studies of the Ocular Complications of AIDS (SOCA) Research Group.

Am J Ophthalmol. 2013 Feb;155(2):206-212.e5. doi: 10.1016/j.ajo.2012.07.019. Epub 2012 Oct 12.

14.

Influence of the social context on use of surgical-lengthening and group-empowering coping strategies among people with dwarfism.

Fernández S, Branscombe NR, Gómez A, Morales JF.

Rehabil Psychol. 2012 Aug;57(3):224-35. doi: 10.1037/a0029280.

PMID:
22946610
15.

Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.

Yu B, Morales JF, O'Rourke SM, Tatsuno GP, Berman PW.

PLoS One. 2012;7(8):e43903. doi: 10.1371/journal.pone.0043903. Epub 2012 Aug 22.

16.

Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy.

Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL; Studies of the Ocular Complications of AIDS Research Group.

Am J Ophthalmol. 2012 Jun;153(6):1016-24.e5. doi: 10.1016/j.ajo.2011.11.014. Epub 2012 Feb 4.

17.

Rejected and excluded forevermore, but even more devoted: irrevocable ostracism intensifies loyalty to the group among identity-fused persons.

Gómez A, Morales JF, Hart S, Vázquez A, Swann WB Jr.

Pers Soc Psychol Bull. 2011 Dec;37(12):1574-86. doi: 10.1177/0146167211424580.

PMID:
22045779
18.

Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis.

Holbrook JT, Colvin R, van Natta ML, Thorne JE, Bardsley M, Jabs DA; Studies of Ocular Complications of AIDS (SOCA) Research Group.

Am J Ophthalmol. 2011 Oct;152(4):628-637.e1. doi: 10.1016/j.ajo.2011.04.007. Epub 2011 Jul 13.

19.

Association of host genetic risk factors with the course of cytomegalovirus retinitis in patients infected with human immunodeficiency virus.

Sezgin E, van Natta ML, Ahuja A, Lyon A, Srivastava S, Troyer JL, O'Brien SJ, Jabs DA; Studies of the Ocular Complications of AIDS Research Group.

Am J Ophthalmol. 2011 Jun;151(6):999-1006.e4. doi: 10.1016/j.ajo.2010.11.029. Epub 2011 Mar 10.

20.

Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors.

Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C; Ocular Complications of AIDS Research Group.

Clin Infect Dis. 2010 Oct 15;51(8):947-56. doi: 10.1086/656415.

Supplemental Content

Loading ...
Support Center